JP7296882B2 - ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 - Google Patents
ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 Download PDFInfo
- Publication number
- JP7296882B2 JP7296882B2 JP2019547600A JP2019547600A JP7296882B2 JP 7296882 B2 JP7296882 B2 JP 7296882B2 JP 2019547600 A JP2019547600 A JP 2019547600A JP 2019547600 A JP2019547600 A JP 2019547600A JP 7296882 B2 JP7296882 B2 JP 7296882B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- nitrogen
- ring
- oxygen
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023026999A JP2023062180A (ja) | 2016-11-23 | 2023-02-24 | ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426079P | 2016-11-23 | 2016-11-23 | |
| US62/426,079 | 2016-11-23 | ||
| PCT/US2017/062996 WO2018098264A1 (en) | 2016-11-23 | 2017-11-22 | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023026999A Division JP2023062180A (ja) | 2016-11-23 | 2023-02-24 | ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535831A JP2019535831A (ja) | 2019-12-12 |
| JP2019535831A5 JP2019535831A5 (enExample) | 2021-01-07 |
| JP7296882B2 true JP7296882B2 (ja) | 2023-06-23 |
Family
ID=62195630
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547600A Active JP7296882B2 (ja) | 2016-11-23 | 2017-11-22 | ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 |
| JP2023026999A Pending JP2023062180A (ja) | 2016-11-23 | 2023-02-24 | ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023026999A Pending JP2023062180A (ja) | 2016-11-23 | 2023-02-24 | ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11873316B2 (enExample) |
| EP (1) | EP3544987A4 (enExample) |
| JP (2) | JP7296882B2 (enExample) |
| CN (1) | CN110088113A (enExample) |
| MA (1) | MA46905A (enExample) |
| WO (1) | WO2018098264A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| MA46427A (fr) | 2015-10-09 | 2018-08-15 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
| EP3452596A4 (en) | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018041973A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| WO2018098264A1 (en) | 2016-11-23 | 2018-05-31 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2018237194A1 (en) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| AU2018316159A1 (en) | 2017-08-08 | 2020-02-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| CN111108096A (zh) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | 寡核苷酸制备技术 |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| JP2021521140A (ja) | 2018-04-12 | 2021-08-26 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| AU2020241559A1 (en) | 2019-03-20 | 2021-11-11 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
| MX2021012981A (es) | 2019-04-25 | 2022-01-18 | Wave Life Sciences Ltd | Composiciones de oligonucleotido y metodos de uso de las mismas. |
| MX2022014606A (es) | 2020-05-22 | 2023-03-08 | Wave Life Sciences Ltd | Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas. |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| EP4555086A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| EP4555085A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| KR20250113455A (ko) | 2022-11-24 | 2025-07-25 | 프로큐알 테라퓨틱스 Ⅱ 비.브이. | 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드 |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| JP2026510408A (ja) | 2023-03-24 | 2026-04-02 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | 神経障害の処置のためのアンチセンスオリゴヌクレオチド |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2024256620A1 (en) | 2023-06-16 | 2024-12-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
| AU2024287308A1 (en) | 2023-07-13 | 2025-12-18 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| EP4774393A1 (en) | 2023-09-07 | 2026-07-15 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025096809A1 (en) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| AU2024379264A1 (en) | 2023-11-16 | 2026-05-14 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025128799A1 (en) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| AU2024402199A1 (en) | 2023-12-20 | 2026-07-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026050243A1 (en) | 2024-08-26 | 2026-03-05 | Korro Bio, Inc. | Galnac conjugated oligonucleotides for rna editing |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2026093339A1 (en) | 2024-10-29 | 2026-05-07 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd) |
| WO2026122478A1 (en) | 2024-12-02 | 2026-06-11 | Korro Bio, Inc. | Extrahepatic delivery formulations and methods |
| WO2026136663A1 (en) | 2024-12-18 | 2026-06-25 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005089441A (ja) | 2003-08-08 | 2005-04-07 | Toudai Tlo Ltd | 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法 |
| JP2015523316A (ja) | 2012-07-13 | 2015-08-13 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | 不斉補助基 |
| JP2015528002A (ja) | 2012-07-13 | 2015-09-24 | ウェイブ ライフ サイエンス プライベート リミテッド | キラル制御 |
| WO2016079181A1 (en) | 2014-11-19 | 2016-05-26 | Roche Innovation Center Copenhagen A/S | Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3329892A1 (de) * | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | Verfahren zur herstellung von oligonucleotiden |
| WO1989009780A1 (en) * | 1988-04-15 | 1989-10-19 | Chemical Industry Institute Of Toxicology | Site-specific tritium-labeled oligodeoxynucleotides |
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| EP0628394B1 (en) | 1993-06-10 | 1998-08-26 | Idemitsu Petrochemical Co. Ltd. | Injection molding die |
| US6180766B1 (en) | 1993-12-02 | 2001-01-30 | Raymond F. Schinazi | Nucleosides and oligonucleotides containing boron clusters |
| US5571937A (en) | 1994-05-13 | 1996-11-05 | Sloan-Kettering Institute For Cancer Research | Complementary DNA and toxins |
| WO1997009443A1 (en) | 1995-09-05 | 1997-03-13 | Michigan State University | PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp |
| US5869696A (en) | 1996-04-22 | 1999-02-09 | Beckman Instruments, Inc. | Universal solid supports and methods for their use |
| GB9621522D0 (en) | 1996-10-16 | 1996-12-04 | Biocompatibles Ltd | Synthesis of phosphorus compounds |
| US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
| US20030017451A1 (en) * | 2000-12-21 | 2003-01-23 | Hui Wang | Methods for detecting transcripts |
| US7153954B2 (en) * | 2001-07-12 | 2006-12-26 | Santaris Pharma A/S | Method for preparation of LNA phosphoramidites |
| CA2458393A1 (en) | 2001-08-24 | 2003-03-06 | Massachusetts Institute Of Technology | Reagents that facilitate the purification of compounds synthesized on a solid support |
| JP4348044B2 (ja) | 2002-02-12 | 2009-10-21 | 株式会社キラルジェン | 立体規則性の高いジヌクレオシドホスホロチオエートの製造法 |
| US7057062B2 (en) | 2002-04-11 | 2006-06-06 | Isis Pharmaceuticals, Inc. | Process for manufacturing purified phosphorodiamidite |
| US7030230B2 (en) | 2002-10-25 | 2006-04-18 | Isis Pharmaceuticals, Inc. | Process of purifying phosphoramidites |
| GB0229423D0 (en) * | 2002-12-18 | 2003-01-22 | Avecia Ltd | Process |
| JP4580870B2 (ja) | 2003-09-02 | 2010-11-17 | 株式会社キラルジェン | リボヌクレオチド又はリボヌクレオチド誘導体の製造方法 |
| JP4616175B2 (ja) | 2003-09-02 | 2011-01-19 | 株式会社キラルジェン | ５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法 |
| JP4945129B2 (ja) | 2004-01-27 | 2012-06-06 | 株式会社キラルジェン | フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| WO2005085272A1 (ja) | 2004-03-05 | 2005-09-15 | Takeshi Wada | ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| WO2005092909A1 (ja) | 2004-03-25 | 2005-10-06 | Toudai Tlo, Ltd. | 立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法 |
| EP2540734B1 (en) | 2004-04-05 | 2016-03-30 | Alnylam Pharmaceuticals, Inc. | Process and reagents for oligonucleotide synthesis and purification |
| JP2006292394A (ja) | 2005-04-06 | 2006-10-26 | Hiroyuki Yamane | シリカゲルの再生方法 |
| EP1874792B1 (en) * | 2005-04-27 | 2016-04-13 | Sigma-Aldrich Co. LLC | Activators for oligonucleotide and phosphoramidite synthesis |
| US7700567B2 (en) * | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| US7759470B2 (en) * | 2006-02-20 | 2010-07-20 | Roche Diagnostics Operations, Inc. | Labeling reagent |
| WO2009143369A2 (en) | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc. | Method of preparing nucleosides and analogs thereof without using chromatography |
| BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| EP2479182B8 (en) | 2009-09-16 | 2016-07-13 | Wave Life Sciences Japan, Inc. | Novel protecting group for synthesizing rna and derivative thereof |
| JP2011121881A (ja) | 2009-12-09 | 2011-06-23 | Nippon Shinyaku Co Ltd | ホスホロアミダイト化合物の製造法 |
| WO2011108682A1 (ja) | 2010-03-05 | 2011-09-09 | 国立大学法人 東京大学 | リボヌクレオシドホスホロチオエートの製造方法 |
| JP2011184318A (ja) | 2010-03-05 | 2011-09-22 | Univ Of Tokyo | リボヌクレシドｈ−ボラノホスホネート |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| EP2647644B1 (en) | 2010-11-30 | 2020-09-09 | Wave Life Sciences Japan, Inc. | 2'-o-modified rna |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| CN102516337B (zh) | 2011-11-02 | 2014-07-02 | 东南大学 | 3’硫代-2’脱氧核糖-3’硝基吡咯亚磷酰胺单体及其合成方法和应用 |
| CN102675386B (zh) | 2011-12-24 | 2014-07-02 | 河南科技大学 | 一种龙胆苦苷分离提纯方法 |
| SG11201500243WA (en) | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| JP2015119116A (ja) | 2013-12-19 | 2015-06-25 | 株式会社東芝 | 半導体装置 |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| CN103819501B (zh) | 2014-03-19 | 2015-11-04 | 厦门大学 | 一种甲基丙烯基亚磷酰胺单体及其合成方法 |
| CN106255697B (zh) | 2014-04-30 | 2020-04-28 | 安捷伦科技有限公司 | 磷保护基团及其制备方法和用途 |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| MA46427A (fr) | 2015-10-09 | 2018-08-15 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
| WO2017157672A1 (en) | 2016-03-18 | 2017-09-21 | Roche Innovation Center Copenhagen A/S | Acyl-protected l-lna-guanosine monomers |
| JP2019516679A (ja) | 2016-05-04 | 2019-06-20 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | 生物活性剤に関する方法および組成物 |
| EP3452596A4 (en) | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| US20190264267A1 (en) | 2016-07-25 | 2019-08-29 | Wave Life Sciences Ltd. | Phasing |
| WO2018098264A1 (en) | 2016-11-23 | 2018-05-31 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CN111164091B (zh) | 2017-06-02 | 2025-01-07 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| WO2018237194A1 (en) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| WO2019002237A1 (en) | 2017-06-28 | 2019-01-03 | Roche Innovation Center Copenhagen A/S | METHOD OF MULTIPLE COUPLING AND OXIDATION |
| AU2018316159A1 (en) | 2017-08-08 | 2020-02-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| CN111108096A (zh) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | 寡核苷酸制备技术 |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| JP2021521140A (ja) | 2018-04-12 | 2021-08-26 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AU2019392928A1 (en) | 2018-12-06 | 2021-06-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| EP3917497A4 (en) | 2019-02-01 | 2023-06-07 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF |
| AU2020241559A1 (en) | 2019-03-20 | 2021-11-11 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
| JPWO2020196662A1 (enExample) | 2019-03-25 | 2020-10-01 | ||
| EP3958872A4 (en) | 2019-04-25 | 2024-07-03 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| MX2021012981A (es) | 2019-04-25 | 2022-01-18 | Wave Life Sciences Ltd | Composiciones de oligonucleotido y metodos de uso de las mismas. |
| EP3965780A4 (en) | 2019-05-09 | 2023-10-25 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE |
| CA3156176A1 (en) | 2019-10-06 | 2021-04-15 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CA3154768A1 (en) | 2019-10-06 | 2021-04-15 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AU2021230473A1 (en) | 2020-03-01 | 2022-09-22 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| MX2022014606A (es) | 2020-05-22 | 2023-03-08 | Wave Life Sciences Ltd | Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas. |
| AU2021277407A1 (en) | 2020-05-22 | 2022-11-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| CN115989041A (zh) | 2020-08-24 | 2023-04-18 | 波涛生命科学有限公司 | 经工程化为表达adar1的细胞和非人动物及其用途 |
| EP4200616A1 (en) | 2020-08-24 | 2023-06-28 | Wave Life Sciences Ltd. | Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays |
| US20230416847A1 (en) | 2020-09-24 | 2023-12-28 | Mayo Foundation For Medical Education And Research | Screening platforms |
| JP2023548584A (ja) | 2020-11-08 | 2023-11-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| CN116507724A (zh) | 2020-11-08 | 2023-07-28 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| CA3232070A1 (en) | 2021-09-26 | 2023-03-30 | Prashant MONIAN | Oligonucleotide compositions and methods thereof |
| EP4404942A4 (en) | 2021-09-26 | 2026-06-17 | Wave Life Sciences Ltd | Compositions for the Editing of Transcripts MECP2 and Related Processes |
| EP4422645A4 (en) | 2021-10-27 | 2025-12-03 | Wave Life Sciences Ltd | OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS OF USE |
| AU2021471586A1 (en) | 2021-10-27 | 2024-05-09 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| EP4476202A4 (en) | 2022-02-11 | 2026-06-10 | Wave Life Sciences Ltd | STEREOSELECTIVE TECHNOLOGIES FOR CHIRICAL COMPOUNDS |
| US20250197857A1 (en) | 2022-03-02 | 2025-06-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof for exon skipping |
| EP4507700A2 (en) | 2022-04-15 | 2025-02-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods relating thereto |
| CN119452084A (zh) | 2022-05-12 | 2025-02-14 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| EP4569115A4 (en) | 2022-08-11 | 2026-07-15 | Wave Life Sciences Ltd | OLIGONUCLEOTID COMPOSITIONS AND ASSOCIATED PROCESSES |
| EP4753719A1 (en) | 2023-08-03 | 2026-06-10 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
-
2017
- 2017-11-22 WO PCT/US2017/062996 patent/WO2018098264A1/en not_active Ceased
- 2017-11-22 MA MA046905A patent/MA46905A/fr unknown
- 2017-11-22 CN CN201780072663.6A patent/CN110088113A/zh active Pending
- 2017-11-22 US US16/463,328 patent/US11873316B2/en active Active
- 2017-11-22 EP EP17874211.0A patent/EP3544987A4/en active Pending
- 2017-11-22 JP JP2019547600A patent/JP7296882B2/ja active Active
-
2023
- 2023-02-24 JP JP2023026999A patent/JP2023062180A/ja active Pending
- 2023-11-28 US US18/522,146 patent/US12473321B2/en active Active
-
2025
- 2025-07-29 US US19/284,561 patent/US20260193286A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005089441A (ja) | 2003-08-08 | 2005-04-07 | Toudai Tlo Ltd | 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法 |
| JP2015523316A (ja) | 2012-07-13 | 2015-08-13 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | 不斉補助基 |
| JP2015528002A (ja) | 2012-07-13 | 2015-09-24 | ウェイブ ライフ サイエンス プライベート リミテッド | キラル制御 |
| WO2016079181A1 (en) | 2014-11-19 | 2016-05-26 | Roche Innovation Center Copenhagen A/S | Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages |
Also Published As
| Publication number | Publication date |
|---|---|
| MA46905A (fr) | 2019-10-02 |
| US20240368207A1 (en) | 2024-11-07 |
| EP3544987A1 (en) | 2019-10-02 |
| WO2018098264A1 (en) | 2018-05-31 |
| JP2019535831A (ja) | 2019-12-12 |
| JP2023062180A (ja) | 2023-05-02 |
| US20190375774A1 (en) | 2019-12-12 |
| US11873316B2 (en) | 2024-01-16 |
| US20260193286A1 (en) | 2026-07-09 |
| CN110088113A (zh) | 2019-08-02 |
| EP3544987A4 (en) | 2020-11-18 |
| US12473321B2 (en) | 2025-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023062180A (ja) | ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 | |
| US12428442B2 (en) | Compounds, compositions and methods for synthesis | |
| AU2021286276B2 (en) | Compositions and methods for phosphoramidite and oligonucleotide synthesis | |
| EP4476202A1 (en) | Stereoselective technologies for chiral compounds | |
| AU2026202225A1 (en) | Technologies useful for oligonucleotide preparation | |
| JP2024105256A (ja) | オリゴヌクレオチド調製のための技術 | |
| JP5847700B2 (ja) | リボヌクレオシドホスホロチオエートの製造方法 | |
| KR20120013537A (ko) | 수율 및 순도가 개선된 데시타빈의 제조방법 | |
| WO2005085271A1 (ja) | ２ ‘水酸基を修飾された新規人工ｒｎａ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201120 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211214 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220613 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221026 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230224 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230308 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20230308 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230317 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230323 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230531 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230613 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7296882 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |